NYSE · CIK 0000894158
TOVX Theriva Biologics, Inc.
Insider trading from SEC Form 4. Last filing Jan 6, 2026.
Theriva Biologics, Inc. (TOVX) has 8 SEC Form 4 filings on file from 4 insiders, the latest filed on Jan 6, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Theriva Biologics, Inc., scored.
Transactions
Every row filed, 8 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Jeffrey J Kraws director | AGrant or award Stock Options (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jan 6, 2026 |
| Jan 5, 2026 | John J Monahan director | AGrant or award Stock Options (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jan 6, 2026 |
| Jan 5, 2026 | Steven A Shallcross CEO and CFO | AGrant or award Stock Options (right to buy)derivative | +475,000 | $0.00 | $0 | 475,000 | Jan 6, 2026 |
| Jan 5, 2026 | Jeffrey Alan Wolf director | AGrant or award Stock Options (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jan 6, 2026 |
| Apr 29, 2025 | Jeffrey J Kraws director | AGrant or award Stock Options (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 1, 2025 |
| Apr 29, 2025 | John J Monahan director | AGrant or award Stock Options (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 1, 2025 |
| Apr 29, 2025 | Steven A Shallcross CEO and CFO | AGrant or award Stock Options (right to buy)derivative | +190,000 | $0.00 | $0 | 190,000 | May 1, 2025 |
| Apr 29, 2025 | Jeffrey Alan Wolf director | AGrant or award Stock Options (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 1, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jeffrey J Krawsdirector
- John J Monahandirector
- Steven A ShallcrossCEO and CFO
- Jeffrey Alan Wolfdirector
Questions about TOVX
Answered from the filings on this page, as of the latest one.
Are insiders buying TOVX?
No. In the last 90 days no insider at Theriva Biologics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TOVX on the open market?
No open-market trade has been scored at Theriva Biologics, Inc.. The latest Form 4 on file was filed on Jan 6, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Theriva Biologics, Inc.?
4 people have filed a Form 4 at Theriva Biologics, Inc., among them Jeffrey J Kraws (director), John J Monahan (director), Steven A Shallcross (CEO and CFO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.